Rebirthel are preparing the first clinical trial conducted in humans for acute myeloid leukemia to evaluate safety and efficacy. Learn more about the Kyoto-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Kajikawa Masunori.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?